Abstract | AIM: METHODS: PubMed, Cochrane library databases, China National Knowledge infrastructure (CNKI) and WanFang database up to November 2021 were systematically searched. The following search terms were used: ' trastuzumab originator', and ' trastuzumab biosimilar'. No language restriction was imposed. The reference lists of all retrieved articles were also reviewed to identify additional articles missed by using these search terms. RESULTS: We got 10 studies to conduct network meta-analysis to evaluate efficacy and serious adverse reactions among various trastuzumab biosimilars and trastuzumab originator. The overall response rate (ORR) and pathological complete response (pCR) of SB3 were worse than trastuzumab originator significantly, while the ORR and pCR of other trastuzumab biosimilars had not yet reached statistical differences compared with each other. The cumulative ranking curve (SUCRA) probability indicated that the ORR from best to worst was CT-P6, Herceptin, HLX02, PF-05280014, R-TPR-016, BCD-022, MYL-1401O, SB3, and the pCR from best to worst was PF-05280014, CT-P6, Herceptin, ABP-980, SB3. The serious adverse events (SAEs) of CT-P6 were more than Herceptin and MYL-1401O significantly, while the SAEs of other trastuzumab biosimilars had not statistical differences. The SUCRA probability indicated that the SAEs from best to worst was MYL-1401O, Herceptin, PF-05280014, SB3, HLX02, BCD-22, CT-P6. CONCLUSION:
|
Authors | Tong Liu, Duo Liu, Yao Jin, Mei Dong |
Journal | Immunopharmacology and immunotoxicology
(Immunopharmacol Immunotoxicol)
Vol. 44
Issue 6
Pg. 809-815
(Dec 2022)
ISSN: 1532-2513 [Electronic] England |
PMID | 35708278
(Publication Type: Meta-Analysis, Systematic Review, Journal Article)
|
Chemical References |
- ABP-980
- Biosimilar Pharmaceuticals
|
Topics |
- Humans
- Female
- Biosimilar Pharmaceuticals
(adverse effects)
- Breast Neoplasms
(drug therapy)
- Network Meta-Analysis
- China
|